Thu, Aug 21, 2014, 2:28 AM EDT - U.S. Markets open in 7 hrs 2 mins

Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

weightbayou 200 posts  |  Last Activity: Aug 19, 2014 2:05 PM Member since: Jul 5, 2003
  • Thanks in advance.

    Sentiment: Strong Buy

  • Reply to

    Franklin Salisbury

    by sundayglf Jun 4, 2014 6:39 AM
    weightbayou weightbayou Jun 7, 2014 7:10 PM Flag

    Yes. He is a big edition. I feel that Entremed should get some good news soon.

    Sentiment: Strong Buy

  • weightbayou weightbayou Jun 7, 2014 7:01 PM Flag

    DEC-205 has already shown good results. You can see my post earlier today.

    Sentiment: Strong Buy

  • Just last month a HIV trial ended at Rockeller Univ. It used DEC-205 technology also.
    Immune-based therapies for cancer are generating substantial interest because of the success of immune checkpoint inhibitors. This study aimed to enhance anticancer immunity by exploiting the capacity of dendritic cells (DCs) to initiate T cell immunity by efficient uptake and presentation of endocytosed material. Delivery of tumor-associated antigens to DCs using receptor-specific monoclonal antibodies (mAbs) in the presence of DC-activating agents elicits robust antigen-specific immune responses in preclinical models. DEC-205 (CD205), a molecule expressed on DCs, has been extensively studied for its role in antigen processing and presentation. CDX-1401 is a vaccine composed of a human mAb specific for DEC-205 fused to the full-length tumor antigen NY-ESO-1. This phase 1 trial assessed the safety, immunogenicity, and clinical activity of escalating doses of CDX-1401 with the Toll-like receptor (TLR) agonists resiquimod (TLR7/8) and Hiltonol (poly-ICLC, TLR3) in 45 patients with advanced malignancies refractory to available therapies. Treatment induced humoral and cellular immunity to NY-ESO-1 in patients with confirmed NY-ESO-1–expressing tumors across various dose levels and adjuvant combinations. No dose-limiting or grade 3 toxicities were reported. Thirteen patients experienced stabilization of disease, with a median duration of 6.7 months (range, 2.4+ to 13.4 months). Two patients had tumor regression (~20% shrinkage in target lesions). Six of eight patients who received immune-checkpoint inhibitors within 3 months after CDX-1401 administration had objective tumor regression. This first-in-human study of a protein vaccine targeting DCs demonstrates its feasibility, safety, and biological activity and provides rationale for combination immunotherapy strategies including immune checkpoint blockade.
    Copyright © 2014, American Association for the Advancement of Scienc

    Sentiment: Strong Buy

  • weightbayou weightbayou Jun 6, 2014 7:12 PM Flag

    Trust me, it just ended, regardless what the original completion date was.

    DCVax Plus Poly ICLC in Healthy Volunteers
    This study has been completed.
    Rockefeller University
    Information provided by (Responsible Party):
    Rockefeller UniversityClinicalTrials.gov Identifier:
    NCT01127464
    First received: May 19, 2010
    Last updated: May 7, 2014
    Last verified: May 2014
    History of Changes Full Text View Tabular ViewNo Study Results PostedDisclaimerHow to Read a Study Record Purpose
    DCVax-001 is a recombinant protein vaccine designed to prevent and potentially treat human immunodeficiency virus (HIV) infection. The vaccine is composed of a fusion protein containing a human monoclonal antibody specific for the dendritic cell receptor, DEC-205 (CD205), and the HIV gag p24 protein. The vaccine is designed to target HIV antigens directly to endocytic pathways in dendritic cells (DCs) that allow for efficient processing and presentation of multiple HIV peptides on both MHC class I and II products, which will induce HIV-specific CD8+ and CD4+ T cells. This vaccine candidate must be combined with appropriate immunostimulants (adjuvants) to induce immunity to the antigen. In the proposed clinical trial we will use poly ICLC (Hiltonol) from Oncovir, Inc as the adjuvant.

    Sentiment: Strong Buy

  • Then you will see powerful gains in CLDX.

    Celldex and Rockefeller University investigators are collaborating on an effort to develop a vaccine against the human immunodeficiency virus (HIV), the virus known to cause Acquired Immune Deficiency Syndrome (AIDS). The vaccine, called DCVax-001, is an APC-targeted vaccine consisting of a fusion protein of a human monoclonal antibody with specificity for the dendritic cell receptor, DEC-205 linked to an HIV antigen. This program has been funded through a grant from the Bill & Melinda Gates Foundation. The vaccine is currently being tested in a Phase 1 trial in healthy volunteers at Rockefeller University.

    Sentiment: Strong Buy

  • weightbayou weightbayou Jun 6, 2014 5:24 PM Flag

    Next week cldx could add $4 and that would set the stage for $40 fairly quickly. Too many irons in the fire to be so low priced.

    Sentiment: Strong Buy

  • weightbayou weightbayou Jun 6, 2014 5:18 PM Flag

    Next week cldx could add $4 and that would set the stage for $40 fairly quickly. Too many irons in the fire to be so low priced.

    Sentiment: Strong Buy

  • weightbayou weightbayou Jun 6, 2014 12:47 PM Flag

    For a long time the trial below said active, not recruiting. It is now completed. DEC-205 is the same technology that Celldex uses in some of its products. If the trial shows good results that would be positive for Celldex.

    DCVax Plus Poly ICLC in Healthy Volunteers
    This study has been completed.
    Rockefeller University
    Information provided by (Responsible Party):
    Rockefeller UniversityClinicalTrials.gov Identifier:
    NCT01127464
    First received: May 19, 2010
    Last updated: May 7, 2014
    Last verified: May 2014
    History of Changes Full Text View Tabular ViewNo Study Results PostedDisclaimerHow to Read a Study Record Purpose
    DCVax-001 is a recombinant protein vaccine designed to prevent and potentially treat human immunodeficiency virus (HIV) infection. The vaccine is composed of a fusion protein containing a human monoclonal antibody specific for the dendritic cell receptor, DEC-205 (CD205), and the HIV gag p24 protein. The vaccine is designed to target HIV antigens directly to endocytic pathways in dendritic cells (DCs) that allow for efficient processing and presentation of multiple HIV peptides on both MHC class I and II products, which will induce HIV-specific CD8+ and CD4+ T cells. This vaccine candidate must be combined with appropriate immunostimulants (adjuvants) to induce immunity to the antigen. In the proposed clinical trial we will use poly ICLC (Hiltonol) from Oncovir, Inc as the adjuvant.

    Sentiment: Strong Buy

  • weightbayou weightbayou Jun 5, 2014 11:31 PM Flag

    It is also possible that Celldex could present cdx-011 data at the San Antonio Breast Cancer Symposium at the end of the year.

    Sentiment: Strong Buy

  • There is a big difference between last year and now. Celldex has a collaboration with BMY and ONTY. On top of that, cdx-301 and cdx-1401 are in new trials (even together in a combo trial).

    Sentiment: Strong Buy

  • Reply to

    Who next on the Varli train, Celgene, Merck?

    by weightbayou May 31, 2014 4:41 PM
    weightbayou weightbayou May 31, 2014 10:07 PM Flag

    Like, I won't get my hopes up too much. I do believe there is a sea change going on though. Celldex signed two deals within about a 10 day period. Within the next 30 days you could see at least one more deal. The more other companies want to try their drugs in combo with cdx-1127 the better. That gives cdx-1127 more shots at being effective in trials. Next week might prove pivotal as to what direction the stock takes.

    Sentiment: Strong Buy

  • Reply to

    Who next on the Varli train, Celgene, Merck?

    by weightbayou May 31, 2014 4:41 PM
    weightbayou weightbayou May 31, 2014 6:15 PM Flag

    Either will work for me. I want to see Celldex steaming ahead like a freight train.

    Sentiment: Strong Buy

  • Novartis?

    Sentiment: Strong Buy

  • weightbayou weightbayou May 31, 2014 4:15 PM Flag

    Frank, already two companies are on the Varli train. I believe a slew of biotechs/pharma will climb aboard. Panic might be setting in for some companies who have not signed a deal yet. I can see $40 this year.

    Sentiment: Strong Buy

  • Now we have a BMY collaboration to boot!

    Sentiment: Strong Buy

  • weightbayou by weightbayou May 26, 2014 2:53 PM Flag

    ENMD-2076 is currently in Phase 2 advanced soft tissue sarcoma and Phase 2 ovarian clear cell carcinoma, trials at Princess Margaret Cancer Centre in Toronto. ASCO will be held May 30 – June 3, 2014 in Chicago, IL. The posters will be presented during separate poster sessions listed below and will be available on the EntreMed website after each session.

    ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma. EntreMed is completing a Phase 2 trial of ENMD-2076 in ovarian cancer. In addition, EntreMed is conducting a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma and a Phase 2 study in advanced ovarian clear cell carcinomas. ENMD-2076 has received orphan drug designation from the U.S. FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.

    Sentiment: Strong Buy

  • If Pfizer was smart it would offer a fraction of that $118 billion for Celldex. CLDX will be much, much higher a year from now.

    Sentiment: Strong Buy

  • It would seem like a good fit.

    Sentiment: Strong Buy

  • weightbayou by weightbayou May 21, 2014 10:51 AM Flag

    Nice..

    Sentiment: Strong Buy

ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.